BioSpace News Archive

Compugen Ltd. today announced that it will present pre-clinical data on its lead pre-clinical asset COM503 in an oral presentation at the 20th CIMT annual meeting, Europe’s Cancer Immunotherapy Meeting, on May 3-5, 2023, in Mainz, Germany.

Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company’s execution of an agreement with Novartis.

Nephros, Inc. today announced that it will file its first-quarter financial results on Wednesday, May 10, 2023 after market close and will host a conference call that same day at 4:30pm ET.

Evelo Biosciences, Inc. today announced updates to its clinical programs.

Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively “Endo”) have executed an agreement with Slayback Pharma LLC to distribute Slayback’s Prevduo ™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) announced today that its management team will present at the BofA Securities Health Care Conference 2023 on Wednesday, May 10, 2023.

Fortive Corporation (“Fortive”) (NYSE: FTV) today announced financial results for the first quarter 2023.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended March 31, 2023.

electroCore, Inc. announced that the National Institute on Drug Abuse, part of the National Institutes of Health, has awarded Emory University and the Georgia Institute of Technology a 3-year, $6.0 million grant through the NIH Helping to End Addiction Long Term Initiative to conduct a pivotal clinical trial of gammaCore for the treatment of opioid use disorder.

Avenge Bio, Inc. today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.